A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects with Moderately to Severely Active Crohns Disease
A study for patients with moderately to severely active Crohn's Disease using study drug GS-5745
Sponsor: Gilead
Enrolling: Male and Female Patients
IRB Number: AAAP4204
U.S. Govt. ID: NCT02405442
Contact: Tanjina Razzaque: 212-342-1464 / tr2432@cumc.columbia.edu
Additional Study Information: This study is for patients that have been diagnosed with Crohn's Disease, which is an inflammatory disease of the gastrointestinal tract (stomach and intestines). The purpose of this study is to see if study drug GS-5745 is effective in treating people with Crohn's Disease.
This study is closed
Investigator
Simon Lichtiger, MD
Do You Qualify?
Have you been diagnosed with Crohn's Disease? Yes No
Do you suffer from Ulcerative Colitis? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Tanjina Razzaque
tr2432@cumc.columbia.edu
212-342-1464
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE